CSL Limited (ASX:CSL)
168.30
-2.90 (-1.69%)
Aug 21, 2026, 4:10 PM AEST
CSL Limited Revenue
In the fiscal year ending June 30, 2026, CSL Limited had annual revenue of $15.80B USD with 1.54% growth. CSL Limited had revenue of $7.47B in the half year ending June 30, 2026, with 10.64% growth.
Revenue
$15.80B
Revenue Growth
+1.54%
P/S Ratio
3.53
Revenue / Employee
$528.26K
Employees
29,904
Market Cap
80.60B AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 15.80B | 239.00M | 1.54% |
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.21B |
| Mesoblast | 98.02M |
| Clinuvel Pharmaceuticals | 96.30M |
| Neuren Pharmaceuticals | 64.65M |
| BLS Pharmaceuticals | 47.95M |
| PYC Therapeutics | 20.56M |
| Starpharma Holdings | 14.58M |
| Clarity Pharmaceuticals | 10.58M |
CSL Limited News
- 3 days ago - CSL Limited Earnings Call Transcript: H2 2026 - Transcripts
- 3 days ago - CSL Limited Slides: H2 2026 - Filings
- 3 days ago - CSL Limited Earnings release: H2 2026 - Filings
- 3 days ago - CSL Limited Annual report: H2 2026 - Filings
- 3 days ago - Australia's CSL reports 2% fall in annual profit - Reuters
- 23 days ago - CSL to start clinical trials for new immunoglobulin manufacturing process - Reuters
- 25 days ago - CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union - PRNewsWire